Although extrapolating this notion directly to humans is difficult, our data suggest the possibility that a highly HER2-amplified tumor could be effectively treated with a lower dose, especially when used in combination with T, similar to our previous report that when used in combination with T, half the dose of L is as effective as full dose in eradicating the BT474 tumors6. The gene discussed is ERBB2; the disease is neoplasm.